AMARILLO, Texas, Aug. 1 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR) announced today that it has engaged First Security
Van Kasper, an investment banking and brokerage firm, to provide general
financial advisory services to the Company.
Working with First Security Van Kasper, Amarillo Biosciences will assess
various strategic and business alternatives including mergers, strategic
alliances and financing opportunities.
"We are pleased to be associated with First Security Van Kasper, a leading
investment bank with nationally recognized growth stock experts and research
analysts," stated Dr. Joseph M. Cummins, Chairman, President and CEO. He
continued, "This association with First Security Van Kasper should maximize
the inherent value of Amarillo Biosciences."
Amarillo Biosciences, founded in 1984, is a pioneer in the development of
low-dose orally administered interferon alpha as a treatment for a variety of
conditions, including Sjogren's syndrome, fibromyalgia syndrome, hepatitis B
and C and opportunistic infections in patients who are HIV positive. ABI is
conducting a Phase III clinical program in Sjogren's syndrome in the United
States.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the company's Form 10-KSB for the year ended Dec.
31, 1999.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Kathleen L. Kelleher, Chief Operating Officer
of Amarillo Biosciences, Inc., 806-376-1741, #15, or email,
kkelleher@amarbio.com
|
